Brian Leyland-Jones
A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Karn T, Schem C, Young B, Hanusch C, Stickeler E, Huober J, van Mackelenbergh M, Leyland-Jones B, Fehm T, Nekljudova V, Untch M, Gerber B, Holtrich U, Müller V, Meissner T, Weber K, Solbach C, Denkert C, Engels K, Fasching P, Sinn B, Schrader I, Budczies J, Marme F, Loibl S. A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. Clin Cancer Res 2020; 26:1896-1904.
Jan 13, 2020A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Jan 13, 2020Clin Cancer Res 2020; 26:1896-1904
Karn Thomas, Schem Christian, Young Brandon M, Hanusch Claus, Stickeler Elmar, Huober Jens, van Mackelenbergh Marion, Leyland-Jones Brian, Fehm Tanja, Nekljudova Valentina, Untch Michael, Gerber Bernd, Holtrich Uwe, Müller Volkmar, Meissner Tobias, Weber Karsten E, Solbach Christine, Denkert Carsten, Engels Knut, Fasching Peter A, Sinn Bruno V, Schrader Iris, Budczies Jan, Marme Frederik, Loibl Sibylle
Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer
Buechler S, Badve S, Leyland-Jones B, Viale G, Kammler R, Thürlimann B, Willis S, Gökmen-Polar Y, Gray K, Regan M. Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer. JNCI Cancer Spectr 2019; 3:pkz051.
Aug 16, 2019Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer
Aug 16, 2019JNCI Cancer Spectr 2019; 3:pkz051
Buechler Steven A, Badve Sunil S, Leyland-Jones Brian, Viale Giuseppe, Kammler Rosita, Thürlimann Beat, Willis Scooter, Gökmen-Polar Yesim, Gray Kathryn P, Regan Meredith M
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
Leyland-Jones B, Maibach R, Price K, Coates A, Goldhirsch A, Gelber R, Pagani O, Viale G, Rae J, Regan M, Arnould L, Neven P, Harvey V, Gray K, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, BIG 1-98 Collaborative Group. ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. Breast Cancer Res Treat 2015; 154:543-55.
Nov 21, 2015ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
Nov 21, 2015Breast Cancer Res Treat 2015; 154:543-55
Leyland-Jones Brian, Maibach Rudolf, Price Karen N, Coates Alan S, Goldhirsch Aron, Gelber Richard D, Pagani Olivia, Viale Giuseppe, Rae James M, Regan Meredith M, Arnould Laurent, Neven Patrick, Harvey Vernon, Gray Kathryn P, Abramovitz Mark, Bouzyk Mark, Young Brandon, Long Bradley, Kammler Roswitha, Dell'Orto Patrizia, Biasi Maria Olivia, Thürlimann Beat, BIG 1-98 Collaborative Group
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
Leyland-Jones B, Neven P, Treilleux I, Rasmussen B, Maibach R, Price K, Coates A, Goldhirsch A, Pagani O, Viale G, Rae J, Harvey V, Ditzel H, Gray K, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, Lyng M, Regan M. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Breast Cancer Res Treat 2015; 151:373-84.
May 3, 2015CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
May 3, 2015Breast Cancer Res Treat 2015; 151:373-84
Leyland-Jones Brian, Neven Patrick, Treilleux Isabelle, Rasmussen Birgitte Bruun, Maibach Rudolf, Price Karen N, Coates Alan S, Goldhirsch Aron, Pagani Olivia, Viale Giuseppe, Rae James M, Harvey Vernon J, Ditzel Henrik J, Gray Kathryn P, Abramovitz Mark, Bouzyk Mark, Young Brandon, Long Bradley, Kammler Roswitha, Dell'Orto Patrizia, Biasi Maria Olivia, Thürlimann Beat, Lyng Maria B, Regan Meredith M
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
Regan M, Debled M, Maibach R, Price K, Gelber R, Coates A, Goldhirsch A, Rae J, Viale G, Neven P, Ditzel H, Lyng M, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012; 104:441-51.
Mar 6, 2012CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
Mar 6, 2012J Natl Cancer Inst 2012; 104:441-51
Regan Meredith M, Debled Marc, Maibach Rudolf, Price Karen N, Gelber Richard D, Coates Alan S, Goldhirsch Aron, Rae James M, Viale Giuseppe, Neven Patrick, Ditzel Henrik J, Lyng Maria B, Leyland-Jones Brian, Bouzyk Mark, Pagani Olivia, Tang Weining, Kammler Roswitha, Dell'Orto Patrizia, Biasi Maria Olivia, Thürlimann Beat, Breast International Group (BIG) 1-98 Collaborative Group